Tamoxifen (TAM) is a widely prescribed antiestrogen for the control of estrogen receptor (ER)-positive breast cancer, yet its efficacy is reduced due to the development of endocrine resistance and intrinsic patient characteristics that prevent drug response. This evidence concerns the gene ESR1 and breast cancer.